Hi Phaedrus, I just wonder if it may be an opportune time, if an approval is forthcoming, for the company to help promote or clarify with the regulator that understanding of the difference between autologous and allogeneic cell products which you highlighted.
One can argue that the price the company has paid in the last few years in terms of delay to get to where they are today ie. on the cusp of an approval, is a cost worth paying in order to advance the science and effect regulatory change necessary to embrace that science in a formal way. This is because in and of their own, not only are such developments profound when you think about them, but they should in turn also benefit not just the industry, but more specifically the company, given that its suite of product indications that it is working on commercialising and the fact that the company has developed deep understanding of, shall we say, the fears and aspirations of the regulator. All this work ultimately helps justify the company’s claim of being world leading in its field.
MSB Price at posting:
33.5¢ Sentiment: Hold Disclosure: Held
(20min delay)